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A B S T R A C T
Purpose: To evaluate the add-on effect of levetiracetam (LEV) treatment on the EEG and clinical status of
children with continuous spikes-waves during slow sleep (CSWS).
Methods: 20 children with CSWS refractory to other conventional antiepileptic drugs (AEDs) received
LEV 45–50 mg/kg/day as add-on treatment, and were prospectively followed for a minimum period of 18
months. The patient population comprised seven cryptogenic, seven symptomatic and six idiopathic
cases (atypical benign partial epilepsy, aBECTs). The electrographic evaluation included 24 h EEG
recordings taken every six months (minimum of three per child). Electrographically children were
categorised as responders, partial responders or non-responders by comparing changes in the spike
index (SI) during NREM-sleep with baseline SI before initiation of LEV. The clinical efﬁcacy of LEV was
assessed by comparing seizure frequency at the end of follow up with the baseline. The follow up
duration varied from 18 to 53 months.
Results: Electrographic response was observed in 11 patients. Eight patients demonstrated a lasing
response (more than 12 months): ﬁve from symptomatic, two – cryptogenic and one – idiopathic group
respectively. Three children showed a partial response (6–12 months): one from symptomatic and two
from idiopathic group.
Eleven out of the 20 children were seizure free at baseline and during the whole follow up. The rest,
six-symptomatic and three-cryptogenic patients, had seizures prior to LEV treatment initiation. Six
became seizure free after add-on therapy with LEV, and in three children a signiﬁcant reduction of
seizure frequency was observed.
Conclusion: This study suggests that add-on therapy with LEV is more effective in children with CSWS
resulting from a known underlying structural brain lesion (the symptomatic group).
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epileptic syndromes with continuous spikes-waves during
sleep represent a wide spectrum of epileptic conditions which have
CSWS as a common speciﬁc EEG-feature. These conditions are of
variable severity, duration and outcome. During the period when
spike-wave activity during sleep dominates the EEG record, a
marked decrease in performance is usually observed, and can
include impairment of cognitive, language, motor or behavioural
functions.1
The mechanisms underlying these neuropsychological distur-
bances have yet to be clariﬁed. Many studies have attempted to
correlate the amount of spike-wave activity under sleep with the* Corresponding author. Tel.: +45 58 27 11 93; fax: +45 58 27 11 88.
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doi:10.1016/j.seizure.2011.06.007clinical impairment observed in these children. The presence of
CSWS on the EEG is almost certainly enough for the appearance of
cognitive impairments.2 Evidence suggests that suppression of this
epileptic activity can quite dramatically improve these func-
tions.2,3
Successful treatment of epileptic syndromes with CSWS has
always been problematic, usually offering little or no respite from
symptoms, or at best, a transitory response.4 The most commonly
used drugs are sodium valproate, benzodiazepines, ethosuximide,
sultiame and steroids.1,5–8 However there is no general agreement,
whether steroids or antiepileptic drugs should be used as a ﬁrst
choice medication, or on the duration of treatment after reaching
clinical and electrographic improvement. During recent years the
potential efﬁcacy of some new antiepileptic drugs, such as
lamotrigine, topiramate, and, especially, levetiracetam, has been
demonstrated in the treatment of CSWS.9–12 LEV is a water soluble
pyrrolidine derivative and an analogue of piracetam. The efﬁcacy of
LEV as an add-on medication in focal epilepsies has been well
documented.13 However, the mode of action of LEV is notvier Ltd. All rights reserved.
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hypersynchronisation of epileptiform burst ﬁring, thus inhibiting
the spread of spike activity.15 Recently the synaptic vesicle protein
SV2A, has been suggested as a possible binding site for LEV.14 A
beneﬁcial effect of LEV in epileptic syndromes with CSWS has been
reported by several investigators.11,12,16,17 However these reports
have either evaluated a small number of children or followed them
during a short period.
We report on a larger prospective study carried out over a
longer period of time; 20 children were evaluated during a period
of 18–53 months.
2. Patients and methods
We studied 20 children (fourteen boys and six girls) aged
between four and thirteen years with CSWS resulting from various
aetiologies: six cases were idiopathic, seven – cryptogenic and
seven – symptomatic. Age at CSWS detection varied from ﬁve to
ten years, CSWS duration – from ﬁve to 50 months (Table 1). In all
patients the efﬁcacy of the consecutive treatment with the
conventional AEDs (sodium valproate, benzodiazepines, ethosux-
imide, sultiame) was lacking in terms of EEG features and
neuropsychological characteristics. Eleven out of 20 children were
seizure-free before LEV introduction.
Before initiation of LEV therapy all patients underwent
magnetic resonance imaging (MRI), 24-h EEG recording and
neuropsychological testing using Wechsler Intelligence Scale for
Children III (WISC-III) and Wechsler Preschool and Primary Scale of
Intelligence Revised (WPPSI-R). In 4 children the Leiter Interna-
tional Performance Scale was used because of severe cognitive
deterioration and lack of the ability to cooperate with verbal tasks.
The assessment of cognitive development was based on the full IQ
(intelligence quotient) scores: 80–100, normal, 60–80, mild delay,
50–60, moderate delay and <50, severe delay.
LEV was administered as add-on therapy at the doses 45–
50 mg/kg/day. All concomitant AEDs remained unchanged. The
clinical efﬁcacy of LEV treatment was evaluated by comparing theTable 1
Patient clinical characteristics.
Total number n = 20
Gender
Male 14
Female 6
Age (years)
Range 4–13
Epilepsy syndrome diagnosis
aBECTs 6
Epilepsy with CSWS 7
Symptomatic focal epilepsy 7
CSWS aetiology
Idiopathic 6
Cryptogenic 7
Symptomatic: 7
Hypoxic–ischemic encephalopathy 3
Focal polymicrogyria 2
Partial trisomy 13/21 1
Age at CSWS onset (years)
Range 5–10
CSWS duration (months)
Range 5–50
Concomitant AEDsa
VPA 4
STM 5
VPA + CLB 3
VPA + STM 2
STM + CLB 4
STM + LTG 1
VPA + ESM 1
a VPAL: valproate; STM: sultiame; CLB: clobazam; LTG: lamotrigine; ESM:
ethosuximide.seizure frequency at the end of follow up with the baseline. The
follow up period comprised 18–53 months.
2.1. Electrographic criteria for CSWS
The accepted morphology for epileptiform activity was a spike
(duration between 20 and 70 ms) followed by a slow wave, with a
frequency between 1 and 4 Hz. All children in the study had at least
one recording where the percentage of epileptic discharges in
NREM-sleep exceeded 80%.
2.2. Quantiﬁcation of epileptiform activity during sleep
The percentage of epileptiform activity occurring during sleep
can be expressed as the spike index (SI). The method of arriving at
the SI varies from centre to centre. In our centre we use a semi
automatic quantiﬁcation method based on spike-detection, using
patient speciﬁc template matching. The percentage is calculated
using the sum of the periods of NREM-sleep during the whole
night.18
Electrographic data for each child was collected over a
minimum period of 18 months, and for many patients, consider-
ably longer (Tables 2 and 3). The qualitative data (Table 2) included
presence of background slowing on the EEG, the regional location
of the predominant spike-wave activity in wakefulness and sleep.
The mode of distribution of spike-wave activity during sleep was
considered either regional, deﬁned as consistently occurring over
one location/region without spread to the contra-lateral hemi-
sphere, or focal with secondary bilateral synchrony (SBS), as
deﬁned by Blume and Pillay,19 and occurring over both hemi-
spheres.
The quantitative data (Table 3) included: the epilepsy
syndrome, the number of years with known CSWS, the baseline
spike-index (BSI)-deﬁned as the SI from the EEG control prior to the
start of LEV as add-on treatment, the number of months in LEV
treatment (range 18–53 months) and the last spike-index (LSI).
The difference between the BSI and the LSI was deﬁned as the
electrographic response to LEV add-on treatment, and was
subsequently graded as follows:
 Responders: (Grade I) reduction in SI >50%
 Partial responders: (Grade II) reduction in SI between 25 and
50%.
 Non responders: (Grade III) reduction in SI <25% or an increase in
SI.
The electrographic response was also categorised in terms of its
duration. Absence of CSWS on the EEG for more than 12 months
was assessed as lasting response, for 6–12 months – as partial
response.
The number of patients was considered too small for statistical
analysis.
3. Results
3.1. Clinical response
Eleven from 20 children were seizure-free before initiation of
LEV therapy and during whole follow up. Six patients from
symptomatic and three from cryptogenic group had seizures
before LEV introduction. At the end of follow up six out of these
nine children were seizure-free (three symptomatic, three
cryptogenic), and signiﬁcant reduction of seizure frequency was
observed in the remaining three patients. LEV was well tolerated
by all the patients.
Table 2
Electrographic characteristics: qualitative and response grade.
Patient
number
Aetiology Background
slowing
Predominant paroxysmal
abnormality – awake
Predominant paroxysmal
abnormality – asleep
Apparent SBS
or regional
1 Cryptogenic No Right F+pT (R) pT+F Regional
2 Cryptogenic No F/T F->T SBS
3 Cryptogenic No F/P F SBS
4 Cryptogenic Yes F/T F->T SBS
5 Cryptogenic No Right F/T (R) F->T SBS in periods
6 Cryptogenic No Left T (L) T SBS in periods
7 Cryptogenic No Left P/T+F (L) P+F->C SBS
8 Symptomatic No Left F/T F->T SBS
9 Symptomatic Yes Left F/T F SBS
10 Symptomatic No Left P/C/T (L) P/C/T Regional
11 Symptomatic No Left T/C (L) T/C Regional
12 Symptomatic No Right P/C (R) P/C Regional
13 Symptomatic No Right T/P (R) T SBS in periods
14 Symptomatic Yes Right T/P (R) T/P Regional
15 aBECTs No Right C/T/P (R) C/T Regional
16 aBECTs Yes Right P/C + Right F/T (R) P/C
(R) F/T
SBS in periods
17 aBECTs No Right F/T + Right T/C/P (R) F->T
(R) P/T
SBS
18 aBECTs Yes Right T/C (R) T/C Regional
19 aBECTs Yes Right P/T/C + Left P/T/C (R) P/T/C
(L) P/T/C
Regional
20 aBECTs No Right T/C/P (R) T/C/P Regional
Later F Later F Later SBS
F: frontal; T: temporal; pT: post temporal; C: central; P: parietal.
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EEG response is summarized in Table 3. During NREM sleep,
discharges usually show a fronto-central or fronto-temporal
maximum. The general trend in our population with cryptogenic
aetiology was a frontal maximum, sometimes with temporal
spreading and SBS, and they did rather badly on medication. The
exceptions were patients one and ﬁve, one of whom had regional
spike-waves over the frontal and post temporal region, with
accentuation of the post temporal discharges during sleep, and no
SBS. This patient responded well to LEV treatment. Another had
frontal spike-waves and occasional SBS, and also responded well to
LEV treatment.
The symptomatic group had the least tendency to SBS and
generally responded well to LEV treatment. Patients eight and nine
had frontal spike-waves and SBS, but responded well to LEVTable 3
Electrographic characteristics: quantitative and response grade.
Pt Age, years Gender Aetiology BSI 
1 10 F Crypt. 48 
2 5 F Crypt. Not known 
3 8 M Crypt. 70 
4 6 M Crypt. 87 
5 12 M Crypt. 48 
6 6 M Crypt. 65 
7 4 M Crypt. 85 
8 12 M Sympt. 80 
9 13 F Sympt. 65 
10 9 M Sympt. 80 
11 9 M Sympt. 86 
12 10 F Sympt. 86 
13 11 M Sympt. 54 
14 11 F Sympt. 52 
15 7 M Idiopat. 80 
16 9 F Idiopat. 87 
17 7 M Idiopat. 75 
18 4 M Idiopat. 82 
19 6 M Idiopat. 46 
20 5 M Idiopat. Not known 
BSI: baseline spike-wave index; LSI: last spike-wave index. Response grade as describemedication. Patient 14 had two foci, one temporal, which in
periods triggered SBS, but responded well to LEV medication.
In the idiopathic group three patients did not develop SBS.
These patients did not usually exhibit frontal spike-waves, but
tended to show a maximum in the centro-temporo-parietal
regions. Patient 15 responded well to LEV treatment and patient
18 showed a partial response. Patient 16 had two foci, the frontal
focus being the less dominant and occasionally triggering SBS. This
patient also showed a partial response to LEV treatment.
Thus, in cryptogenic group (patients one to seven), two patients
showed a lasting response, and the remaining ﬁve – no response. In
symptomatic group (patients 8–14), all but one, showed improve-
ment: ﬁve – lasting response and one – partial response. In
idiopathic group (patients 15–20), a lasting response was
demonstrated only in one child. Two children showed a partial
response and in three no improvement was observed.Months in LEV treatment LSI Response grade
41 No CSWS I
53 95 III
33 64 III
47 97. III
30 No CSWS I
18 88 III
18 76 III
18 Norm I
43 No CSWS I
26 55 II
30 40 I
18 No CSWS I
45 67 III
25 Norm I
19 No CSWS I
24 56 II
32 89 III
27 60 II
25 46 III
23 80 III
d under Section 2.
Table 4
Cognitive development before and after LEV therapy.
Groups of patients/cognitive development Before LEV
therapy
At the end of
follow-up
Idiopathic (n = 6)
Normal 4 1
Mild delay 1 4
Moderate delay 1 1
Severe delay 0 0
Cryptogenic (n = 7)
Normal 2 0
Mild delay 3 2
Moderate delay 1 2
Severe delay 1 3
Symptomatic (n = 7)
Normal 1 1
Mild delay 2 1
Moderate delay 1 1
Severe delay 3 4
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Before the initiation of LEV therapy four out of six patients in
the idiopathic group had normal cognitive development, one child
– mild and one – moderate delay. In the cryptogenic group two out
of seven children had normal IQ scores, three – mild delay, one –
moderate and one – severe delay in the cognitive development. In
the symptomatic group one patient out of seven had initially
normal cognitive development, two were mildly delayed, two –
moderately and three – severely delayed. The neuropsychological
outcome is presented in Table 4. In both idiopathic and cryptogenic
groups the cognitive development declined, despite the clinical
and electrographical improvement. However in symptomatic
group no signiﬁcant neuropsychological deterioration was ob-
served at the end of follow-up. The duration of CSWS was the main
predictor of the severity of neuropsychological outcome showing a
linear correlation: the longer was the duration of CSWS, the poorer
was the outcome. This data is in accordance with the other
studies.1,20,21
4. Discussion
This is the ﬁrst study showing LEV, as add-on therapy, to be
effective over a long period of time in children with CSWS
resulting from symptomatic epilepsy. Moreover, this study
reveals only partial or no effect in the majority of cases with
CSWS of other aetiologies, namely idiopathic or the classic CSWS
syndrome.
A limited number of previous studies have shown LEV to be
effective in CSWS resulting from various aetiologies. Kramer
et al.16 reported efﬁcacy in seven of 17 children, the duration
and relapse rate unknown. Wang et al.17 demonstrated LEV
efﬁcacy in ﬁve of six children, but two of ﬁve responders
relapsed four and ﬁve months respectively. Capovilla et al.11
observed efﬁcacy in two of three children, (all with symptomatic
epilepsy and CSWS), followed for 15 and 12 months respective-
ly. A partial response was recorded in the third child. Aeby
et al.12 reported improvement of the EEG in seven of 12 children
after a two month period, and the neuropsychological and/or
behaviour improvement in nine. In their study LEV had been
discontinued after one year in four patients because of CSWS
relapse. The only prospective study to date,17 showed no
response to LEV treatment in the four patients treated, their
aetiologies were not speciﬁed.
In our study we report on the efﬁcacy of LEV add-on treatment
in terms of electrographic response, seizure frequency and
neuropsychological outcome. The close temporal associationbetween the epileptic discharges during sleep and the deteriora-
tion of cognitive and behavioural functions is generally accept-
ed,22,23 even though the mechanisms underlying these
disturbances remain unclear. At this present time, the goal of
treatment must be the effective reduction of epileptic discharges
during sleep over as long a period as possible, if not permanently.
Some of the problems experienced in reporting on the apparent
efﬁcacy of a chosen medication in the treatment of CSWS include
spontaneous recovery in some patients, transient electrographic
and clinical changes that are not related to alterations in
medication, and the unpredictability of relapse. We have tried
to overcome these problems by evaluating children over a longer
period and using ﬁxed methods of quantitative and qualitative
evaluation, at a maximum of 6 monthly intervals. Concomitant
medications remained unchanged during the study.
Whilst the three epileptic syndrome groups share many similar
clinical and electrographic manifestations during sleep, the
response to LEV appears to differ between these groups, showing
increased efﬁcacy in the symptomatic group, as was also shown by
Capovilla et al.11
We cannot at this time explain why this should be so, or indeed,
whether it is only a chance ﬁnding.
We considered the presence of SBS, which by deﬁnition
suggests a cortical site of hyperexcitability in the leading
hemisphere, capable of rapid transverse of the corpus callosum.
Experimental data has shown that, the burst ﬁring pattern
associated with spindling in the early sleep stages can develop
into bilateral synchronous self sustaining spike-wave discharges.24
Furthermore, this phenomenon may be age limited.22 Related to
the purpose of our study, we found that children not exhibiting SBS
seemed to respond better to LEV treatment.
Secondly, we considered the location of the predominant
paroxysmal activity. As reported by Blume and Pillay,19 SBS favours
a frontal location – this was a trend we found. The temporal and
parietal paroxysmal locations correlated generally with a better
response to LEV treatment.
5. Conclusion
LEV as an add-on treatment 45–50/mg/kg/day, would seem to
be an effective and lasting treatment for children with CSWS
resulting from symptomatic epilepsy, where the paroxysmal
activity has a regional location without SBS. In the future, further
evaluation using a larger population is required. Additionally, the
mechanisms triggering SBS, and their relevance to the spread of
epileptic discharges in the CSWS-syndrome require further
evaluation.
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